News
Public · Published
CRMD Stock Hits Fresh 52-Week Low On DaVita's Warning Of Sharp 2027 DefenCath Reimbursement Drop
CorMedix shares tumbled nearly 26% on Friday and hit a fresh 52-week low. DaVita's CFO said Medicare's add-on payment for DefenCath, which replaced the expired TDAPA add-on, will drop significantly after early 2027 and stay low or keep declining.
Published:
Updated:
What happened
CorMedix shares tumbled nearly 26% on Friday and hit a fresh 52-week low. DaVita's CFO said Medicare's add-on payment for DefenCath, which replaced the expired TDAPA add-on, will drop significantly after early 2027 and stay low or keep declining.
Confirmed
Global impact / market context
Dialysis companies like DaVita are CorMedix's biggest customers, so lower Medicare payments push CorMedix to cut its prices, squeezing revenue from its flagship product. CorMedix already expects DefenCath revenue to fall to $175-$195 million in 2026 from $258.8 million in 2025.
Analyst inference
The stock's 26% drop and 52-week low show investors are pricing in lasting pricing pressure rather than a one-time payment reset. A smaller per-unit payment to dialysis centers flows directly into lower sales for CorMedix, weakening the profit outlook for its main product.
Analyst inference
What to watch
- Medicare recalculates the post-TDAPA add-on payment every quarter using updated volume and average sales price, so each quarterly update can change how much dialysis centers are paid for DefenCath. Confirmed
- Watch whether DaVita and other dialysis providers press CorMedix for deeper price cuts as their reimbursement shrinks, since lower payments to them typically force CorMedix to charge less. Analyst inference
- Track CorMedix's reported DefenCath revenue against its $175-$195 million guidance for 2026, a range set before this warning, to see if actual sales come in below plan. Proposed